323 related articles for article (PubMed ID: 28699217)
1. Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.
Hindryckx P; Novak G; Bonovas S; Peyrin-Biroulet L; Danese S
Clin Pharmacol Ther; 2017 Oct; 102(4):633-641. PubMed ID: 28699217
[TBL] [Abstract][Full Text] [Related]
2. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
[TBL] [Abstract][Full Text] [Related]
3. De-escalation of medical therapy in inflammatory bowel disease.
Frias Gomes C; Chapman TP; Satsangi J
Curr Opin Pharmacol; 2020 Dec; 55():73-81. PubMed ID: 33160250
[TBL] [Abstract][Full Text] [Related]
4. Treatment with biologic therapies and the risk of cancer in patients with IBD.
Biancone L; Calabrese E; Petruzziello C; Pallone F
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):78-91. PubMed ID: 17268543
[TBL] [Abstract][Full Text] [Related]
5. Methods to avoid infections in patients with inflammatory bowel disease.
Aberra FN; Lichtenstein GR
Inflamm Bowel Dis; 2005 Jul; 11(7):685-95. PubMed ID: 15973124
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.
Mazzola G; Macaluso FS; Adamoli L; Renna S; Cascio A; Orlando A
J Infect; 2017 May; 74(5):433-441. PubMed ID: 28263759
[TBL] [Abstract][Full Text] [Related]
8. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
[TBL] [Abstract][Full Text] [Related]
9. Tuberculosis in the age of biologic therapy.
Hernandez C; Cetner AS; Jordan JE; Puangsuvan SN; Robinson JK
J Am Acad Dermatol; 2008 Sep; 59(3):363-80; quiz 382-4. PubMed ID: 18694676
[TBL] [Abstract][Full Text] [Related]
10. Safety issues with biological therapies for inflammatory bowel disease.
Van Assche G; Vermeire S; Rutgeerts P
Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
[TBL] [Abstract][Full Text] [Related]
11. Emerging biological treatments in inflammatory bowel diseases.
Van Assche G; Vermeire S; Rutgeerts P
Dig Dis; 2006; 24(1-2):131-6. PubMed ID: 16699271
[TBL] [Abstract][Full Text] [Related]
12. [Advances in biologic therapy for inflammatory bowel disease].
Sostegni R; Pera A; Daperno M; Rocca R
Recenti Prog Med; 2008 Jan; 99(1):10-8. PubMed ID: 18389866
[TBL] [Abstract][Full Text] [Related]
13. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease.
Armuzzi A; Gionchetti P; Daperno M; Danese S; Orlando A; Lia Scribano M; Vecchi M; Rizzello F;
Dig Liver Dis; 2016 Apr; 48(4):360-70. PubMed ID: 26821929
[TBL] [Abstract][Full Text] [Related]
14. The role and advances of immunomodulator therapy for inflammatory bowel disease.
Nielsen OH; Coskun M; Steenholdt C; Rogler G
Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):177-89. PubMed ID: 25101818
[TBL] [Abstract][Full Text] [Related]
15. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
16. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
[TBL] [Abstract][Full Text] [Related]
17. The impact of pregnancy on biologic therapies for the treatment of inflammatory bowel disease.
Picardo S; Seow CH
Best Pract Res Clin Gastroenterol; 2020; 44-45():101670. PubMed ID: 32359682
[TBL] [Abstract][Full Text] [Related]
18. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.
Trivedi I; Hanauer SB
Expert Opin Drug Saf; 2015; 14(12):1915-34. PubMed ID: 26559664
[TBL] [Abstract][Full Text] [Related]
19. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970
[TBL] [Abstract][Full Text] [Related]
20. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?].
Gomollón F; Gisbert JP
Gastroenterol Hepatol; 2010 Jan; 33(1):43-53. PubMed ID: 19616870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
